Chu Hunghao, Wang Yadong
Departments of Bioengineering & Surgery, The McGowan Institute for Regenerative Medicine, University of Pittsburgh, 3700 O'Hara Street, Pittsburgh, PA 15261, USA.
Ther Deliv. 2012 Jun;3(6):693-714. doi: 10.4155/tde.12.50.
Therapeutic angiogenesis aims at treating ischemic diseases by generating new blood vessels from existing vasculature. It relies on delivery of exogenous factors to stimulate neovasculature formation. Current strategies using genes, proteins and cells have demonstrated efficacy in animal models. However, clinical translation of any of the three approaches has proved to be challenging for various reasons. Administration of angiogenic factors is generally considered safe, according to accumulated trials, and offers off-the-shelf availability. However, many hurdles must be overcome before therapeutic angiogenesis can become a true human therapy. This article will highlight protein-based therapeutic angiogenesis, concisely review recent progress and examine critical challenges. We will discuss growth factors that have been widely utilized in promoting angiogenesis and compare their targets and functions. Lastly, since bolus injection of free proteins usually result in poor outcomes, we will focus on controlled release of proteins.
治疗性血管生成旨在通过从现有脉管系统生成新血管来治疗缺血性疾病。它依赖于外源性因子的递送以刺激新血管形成。目前使用基因、蛋白质和细胞的策略已在动物模型中证明了疗效。然而，由于各种原因，这三种方法中的任何一种进行临床转化都已证明具有挑战性。根据累积试验，血管生成因子的给药通常被认为是安全的，并且具有现货供应。然而，在治疗性血管生成成为真正的人类治疗方法之前，必须克服许多障碍。本文将重点介绍基于蛋白质的治疗性血管生成，简要回顾近期进展并审视关键挑战。我们将讨论已广泛用于促进血管生成的生长因子，并比较它们的靶点和功能。最后，由于游离蛋白质的推注通常会导致不良结果，我们将专注于蛋白质的控释。
